Skip to main content

Table 1 Sample characteristics

From: Development and validation of the self-management profile for type 2 diabetes (SMP-T2D)

MEASURE

N (%) or Mean (SD)

STUDY 1

147 (100%)

Gender

 

  Male

88 (59.9%)

  Female

59 (40.1%)

Ethnicity

 

  Caucasian

88 (59.9%)

  Black

24 (16.3%)

  Hispanic

21 (14.3%)

  Asian

11 (7.5%)

  Other

3 (2.0%)

Age (at enrollment)

54.6 (10.8)

Treatment Assignment

 

  Sitagliptan

64 (43.5%)

  Pioglitazone

44 (29.9%)

  Exenatide QW

39 (26.5%)

BMI (kg/m^2)

33.7 (5.3)

A1c

8.5 (1.2)

DTSQs frequency of perceived hyperglycemia (0–6)

2.8 (1.7)

DTSQs frequency of perceived hypoglycemia (0–6)

0.9 (1.5)

WHO-5 Well-Being Index total (0–100)

67.6 (18.1)

EQ-5D Visual Analog Scale (0–100)

76.2 (18.4)

EQ-5D Item 3 – Usual Activities (1–3, higher score = more problems)

1.2 (0.4)

IWQOL-Lite total score (0–100)

82.6 (15.5)

STUDY 2

93 (100%)

 Gender

 

  Male

61 (65.6%)

  Female

32 (34.4%)

Ethnicity

 

  Caucasian

76 (81.7%)

  Black

12 (12.9%)

  Other

5 (5.4%)

Age (at enrollment)

50.8 (10.5)

Medication (at enrollment)

 

  Metformin only

61 (65.6%)

  Metformin and TZD

10 (10.8%)

  TZD only

1 (1.0%)

  None

21 (22.6)

Treatment assignment (Exenatide dose)

 

  2 mg, once weekly

22 (23.7%)

  5 mg, once monthly

22 (23.7%)

  8 mg, once monthly

26 (28.0%)

  11 mg, once monthly

23 (24.7%)

Baseline BMI (kg/m^2)

34.1 (5.7)

Baseline A1c

8.3 (1.1)

Baseline DTSQs perceived hyperglycemia

2.8 (1.9)

Baseline DTSQs perceived hypoglycemia

1.0 (1.3)

Change from baseline in BMI (kg/m^2)

−0.4 (5.3)***

Change from baseline in A1c

−1.2 (1.2)***

Change from baseline in DTSQs perceived hyperglycemia

−1.1 (2.1)***

Change from baseline in DTSQs perceived hypoglycemia

0.2 (1.6)

  1. BMI, body mass index; A1c, glycated hemoglobin; SD, standard deviation; *** p <; 0.001 (two-tailed).